Technologies

A non-invasive test for detecting prostate cancer (PC) measures DNA methylation using a unique panel of gene biomarkers. Designed for cancer screening and diagnosis, the test relies on an assay type known to be stable and can be performed on any bodily fluid permitting extraction and concentration of nucleic acids, including blood and urine. This patent-pending technology uses measures of aberrant DNA methylation gene patterns that have been linked to PC. The composite biomarker panel demonstrated 100 percent sensitivity and specificity for PC detection in a pilot study. Because sample analysis can occur in any clinical lab setting, the test can be incorporated into national cancer screening programs.